Clinical Trial Search

Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC

Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months

Primary: Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen — 39 Participants

Primary: Number of Participants With Resectability Rate — 15 Participants

Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: Number of Participants With Acute (Within 3 Months of Treatment) Grade 3 or Greater Gastrointestinal Toxicity — 0 Participants

Primary: The Percentage of Patients That Underwent an R0 Resection — 52 percentage of patients

Primary: CA 19-9 Normalization — 40; 13.6; 30; 50 Percentage of participants — p=0.235

Primary: Overall Survival at 18 Months — 63 percentage of participants

Primary: Local Progression-free Survival (LPFS) at 1-year — 85 percentage of participants

Primary: Percentage Able to Complete Full Course of Preoperative Chemotherapy — 22 Participants

Primary: Rate of Margin Negative Surgical Resection (R0 Resection Rate) — 88 percentage of participants

Primary: Local Progression-free Survival (LPFS) — 22.30801 months

Primary: Local Control Rate — 1 Participants

Primary: Number of Participants With Dose Limiting Toxicity (DLT ) — 0; 1; 0; 0 Participants

Primary: Number of Serious Pre-operative, Operative and Post-operative Adverse Events to 120 Days Post Randomization or to 30 Days Post Surgery, Whichever Comes Last — 40; 36…

Primary: Survival — 37; 31 participants

Primary: Two-year Disease Free Survival. — 26.1 percentage of patients

Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804

Primary: Number of Participants With Dose Limiting Toxicities in the 5 Radiation Sessions in One Week Arm — 0 Participants

Primary: Frequency of R0 Resection — 11; 2 Participants

Primary: Recurrence Free Survival — 15.6 months

Primary: Number of Participants With Relapse-free Survival — 3; 2 Participants

Primary: Progression-free Survival at 6 Months — 82 percentage of participants

Primary: Number of Participants With Adverse Events — 3; 4; 10; 2 participants

Primary: Overall Survival at 2 Years — 0.54 proportion of patients

Primary: Feasibility of Adjuvant FOLFOX-A — 18 Participants

Primary: Percentage of Patients With Pathologic Complete Response — 0 percentage of participants

Primary: Progression Free Survival Rate — 67 percentage of participants